Day: September 8, 2021

EWING, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, will participate and host investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference being held on September 13-15, 2021. About Antares Pharma Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies...

Worldwide Holdings Delaware will soon become fully reporting with its stock tradable on the OTC exchange Las Vegas, Nevada, Sept. 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Worldwide Holdings Delaware Corp. (OTC:WWDH) announces that it has been approved by OTC Markets to upload current financial data to their website for public dissemination.  The company will soon be fully reporting per SEC regulations, working to raise capital through a Regulation A stock offering as it moves into full production. To launch production of renewable energy systems, WWDH is in discussions with several companies to produce state-of-the-art equipment covering all commercial applications, including possible contracts with African countries through aid programs. The new management team has a roadmap developed to expand its production of Healthcare...

MIAMI, Sept. 08, 2021 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that the Company will present at the following upcoming healthcare investor conferences.H.C. Wainwright 23rd Annual Global Investment Conference: September 13-15, 2021Presentation available on September 13, 2021, at 7:00 AM ETOppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23, 2021Presentation: September 21, 2021, at 1:15 PM – 1:55 PM ETCantor Virtual Global Healthcare Conference: September 27-30, 2021Presentation: September 28, 2021, at 9:20 AM – 9:50 AM ETThe presentations will be available at https://verupharma.com/. The webcast will be archived and accessible on the web site for...

Los Angeles, CA, Sept. 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — US Nuclear (OTCQB: UCLE) and partners (Grapheton, Solar System Resources, and Four Point) were one of 21 (out of 350) companies that have been shortlisted for the next phase in the Charge On Innovation Challenge, which is a global competition under the patronage of 17 mining companies from around the world, including BHP, RioTinto, and Vale.  The competition aims to electrify the largest trucks in the world, ultra-class mining trucks, to help reduce the consumption of diesel fuel and significantly cut harmful emissions.  It has already attracted massive global attention, with more than 350 vendors registering their interest from 21 countries, and more than 80 applications submitted from the best engineering companies in the world.  Of the 80 applications...

– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest Phase 3 PFIC trial to date – BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), administered as a once-daily capsule or opened and sprinkled onto soft foods and which does not require refrigeration.The MHRA authorization...

Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing capability, including an update on its discovery-stage alpha-1 antitrypsin deficiency (“AATD”) program, as well as its preclinical neurology portfolio and PRISMTM platform advancements at its 2021 Analyst and Investor Research Webcast taking place Tuesday, September 28, 2021 at 10:00 a.m. EDT. The Research Webcast will feature presentations from Wave management and also review data being presented at the TIDES USA: Oligonucleotides & Peptide Therapeutics meeting and the...

RIDGEFIELD PARK, NEW JERSEY, Sept. 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — LIFEQUEST WORLD CORP (LQWC) subsidiary, Biopipe Global has developed the world’s only highly scalable onsite sludge and chemical free sewage wastewater treatment technology. This plant with capacity of 5m3/day (1,320 gallons per day) is being installed at a recently upgraded facility of a wine and spirits maker with a portfolio of highly desirable global luxury brands. Tanmay Pawale, the Chief Operating Officer of Biopipe, said, “We are pleased to get this order for one of the finest makers of wine and spirits in the world. The plant has already been delivered to the site but some site-specific work remains to be done. We are on target to commission this plant by the end of this month. Once we have successfully demonstrated Biopipe’s treatment...

HOUSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today announced its Patriot Glass Solutions division has received a purchase order from a Texas hospital for $136,000, bringing its total orders since June 2021 to more than $1.1 million. The custom printed film is being installed on the interior of the hospital to provide privacy from an outdoor courtyard, on two exterior curtain walls, and a skywalk. The Patriot Glass Solutions installation is expected to start mid-September and is being structured as a two-year project. Patriot Glass Solutions protects personal, commercial and government property from looting, rioting, break-ins, and gunfire. Its leading products are C-Bond BRS (ballistic-resistant film system) and C-Bond Secure, as well as other...

FREMONT, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer cleaning technologies for advanced semiconductor devices, today provided an update on the status of the proposed initial public offering (“IPO”) and listing of shares of ACM’s operating subsidiary ACM Research (Shanghai), Inc. (“ACM Shanghai”) on the Shanghai Stock Exchange’s Sci-Tech innovAtion boaRd. ACM Shanghai plans to begin preliminary in-person and videoconference meetings with qualified IPO investors in China on September 8, 2021. Further details regarding the timing of the IPO are expected to be posted by the Shanghai Stock Exchange when available. ACM estimates that the IPO and listing process will be completed during the fourth quarter of 2021, but the completion and timing of the IPO are subject...

Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021 BURNABY, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone with the approval of a clinical trial application (CTA) in Europe, triggering an aggregate payment of $10.0 million to Xenon. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “This $10 million regulatory milestone from our collaboration with Neurocrine Biosciences marks a significant achievement. We look forward to Neurocrine Biosciences initiating a Phase 2 clinical trial for NBI-921352 for...